U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644559) titled 'A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer' on May 26.
Brief Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
G12D Mutated KRAS
Intervention:
DRUG: VS-7375
Taken by mouth
DRUG: cetuximab
Subcutaneous infusion
Recruitment Status: RECRUITING
Sponsor: Verastem, Inc.
Disclaimer: Curated by HT Syndication....